Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Sorbitol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.55 |
| ▸ | TOP1 known ✓ | P11387 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.92 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.92 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mannitol SCHEMBL28366079 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL28366077 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL2069640 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL21647170 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL22320723 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL1745993 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL3978613 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL20492652 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL22320722 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL29635022 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723819-B1 | WOUND DRESSING | ANIMAL ETHICS PTY LTD (AU) | 2026-04-22 | — | — | EP | claimed |
| CN-120082881-A | Red rust cleaning and passivating complexing agent for stainless steel medical pipeline and preparation method and application thereof | 广东凯盟钝化防锈技术有限公司 | 2025-06-03 | — | — | CN | claimed |
| EP-3976018-B1 | COMPOSITION FOR USE IN THE TREATMENT OF FOOT AND MOUTH DISEASE (FMD), SCABBY MOUTH (ORF), PICORNAVIRUS, PARAPOXVIRUS, AND A PATHOGENIC DISEASE CAUSING POX LESIONS | ANIMAL ETHICS PTY LTD (AU) | 2024-08-28 | — | — | EP | claimed |
| WO-2024126636-A1 | PH-STABLE BIOTECHNOLOGY COMPOSITION BASED ON LACCASE FOR TARGETED DEGRADATION OF COLOURED MELANOIDINES AND/OR PHENOLIC ORGANIC COMPOUNDS ON DENSE SURFACES | SkyLab AG (CH) | 2024-06-20 | — | — | WO | claimed |
| CN-116879209-A | Method for detecting CpG content in double-adjuvant recombinant novel coronavirus vaccine (pichia pastoris) | 长春卓谊生物股份有限公司 | 2023-10-13 | — | — | CN | claimed |
| US-20220226297-A1 | Method of Disease Control | ANIMAL ETHICS PTY LTD (AU) | 2022-07-21 | — | — | US | claimed |
| EP-3976018-A1 | METHOD OF DISEASE CONTROL | Animal Ethics Pty Ltd (AU) | 2022-04-06 | — | — | EP | claimed |
| EP-3976011-A1 | PAIN RELIEVING SPRAY | Animal Ethics Pty Ltd (AU) | 2022-04-06 | — | — | EP | claimed |
| CN-112972683-A | Locally administered medicinal composition of gellinzomib and the like | 刘力 | 2021-06-18 | — | — | CN | claimed |
| CN-112933075-A | Topical administration of kudzu root related pharmaceutical compositions | 刘力 | 2021-06-11 | — | — | CN | claimed |
| CN-110960551-A | Novel electrolyte sorbitol chiral resuscitation medicine composition | 刘力 | 2020-04-07 | — | — | CN | claimed |
| WO-2020024500-A1 | SYNTHESIS METHOD FOR LOW-TRANSOLEATE CONTENT POLYSORBATE 80 FOR INJECTION | 南京威尔药业股份有限公司 | 2020-02-06 | — | — | WO | claimed |
| EP-3723819-B1 | WOUND DRESSING | ANIMAL ETHICS PTY LTD (AU) | 2026-04-22 | — | — | EP | disclosed |
| CN-120082881-A | Red rust cleaning and passivating complexing agent for stainless steel medical pipeline and preparation method and application thereof | 广东凯盟钝化防锈技术有限公司 | 2025-06-03 | — | — | CN | disclosed |
| WO-2025097213-A1 | COMPOSITIONS AND METHODS FOR TREATING HALITOSIS | THE UNIVERSITY OF MELBOURNE (AU) | 2025-05-15 | — | — | WO | disclosed |
| EP-3976018-B1 | COMPOSITION FOR USE IN THE TREATMENT OF FOOT AND MOUTH DISEASE (FMD), SCABBY MOUTH (ORF), PICORNAVIRUS, PARAPOXVIRUS, AND A PATHOGENIC DISEASE CAUSING POX LESIONS | ANIMAL ETHICS PTY LTD (AU) | 2024-08-28 | — | — | EP | disclosed |
| EP-0533609-A1 | Process for manufacturing gasified candy | Bayes Turull, Ramon (ES) | 1993-03-24 | — | — | EP | disclosed |
| US-5165951-A | Heating, pressurization in inert gas, cooling in crystallizer, solidification; bubble retention; popping noise | GALLART RAMON E (ES) | 1992-11-24 | — | — | US | disclosed |
| US-5051500-A | Method of preparing a randomly-bonded polysaccharide | A. E. STALEY MANUFACTURING COMPANY (US) | 1991-09-24 | — | — | US | disclosed |
| US-4375394-A | Electrolytic process for the preparation of ethylene glycol and glycerine | EASTMAN KODAK COMPANY (US) | 1983-03-01 | — | — | US | disclosed |